palmitoylethanolamide.com.au
HomeResearchMireille 2019

Role of pannexin-1 in the cellular uptake, release and hydrolysis of anandamide by T84 colon cancer cells

Mireille Alhouayek, René Sorti, Jonathan D Gilthorpe, Christopher J Fowler. Sci Rep. 2019 May 20;9(1):7622.

Laboratory studyHumans

Design
Laboratory study
Subjects
Human T84 colon cancer cells, PC3 prostate cancer cells and SH-SY5Y neuroblastoma cells
Dose used in the study
Palmitoylethanolamide applied to cells for uptake assays; concentration not stated in the abstract
Duration
Uptake and release measured over minutes
What was measured
Whether pannexin-1 inhibitors (carbenoxolone, mefloquine) and substrate SR101 change uptake, hydrolysis and release of anandamide, 2-AG and palmitoylethanolamide.

What the authors reported

This lab study found:

  • T84 cells expressed pannexin-1 and released ATP in a way the inhibitors reduced.
  • The inhibitors did not change uptake or hydrolysis of anandamide, and uptake of 2-AG and palmitoylethanolamide was likewise unaffected.
  • Release of tritium from labelled cells was increased rather than blocked.
  • Anandamide uptake in PC3 cells was also not inhibited.
  • Pannexin-1 does not appear to govern uptake in these cells.

Limits of this study

A cell-culture study; it cannot show effect in people. Palmitoylethanolamide was a secondary test compound. The authors declare no competing interests.

Source

PubMed 31110238 · doi:10.1038/s41598-019-44057-x

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.